GSK tips its hat on new deals, reviews incentives as Hal Barron cooks up a turnaround plan for its lackluster R&D group
Later in Q2, new GSK research chief Hal Barron is expected to present a detailed outline of his turnaround plan for pharma R&D, which has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
